Drug Delivery
Smart Nanoparticles Convert 'Cold' Tumors to 'Hot' in Immunotherapy Breakthrough
Scientists develop tumor microenvironment-responsive polymeric nanoparticles that precisely deliver immunotherapy, turning immunologically 'cold' tumors 'hot' and expanding treatment efficacy to more cancer patients.
Oncotelic Therapeutics Advances Nanoparticle Drug Delivery Platform to Improve Cancer Treatment Outcomes
Oncotelic Therapeutics is leveraging its Deciparticle platform and Sapu003 program to enhance drug delivery for existing cancer therapies, addressing key challenges in oncology treatment.
Oncotelic Therapeutics Highlighted in BioMedWire Editorial as Drug-Delivery Market Nears $410 Billion Opportunity
Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial examining the growing drug-delivery market, highlighting its Sapu003 and Deciparticle platform as nanotechnology-driven approaches to improve existing therapies.
Platform Biotech Models Attract Investor Attention as Drug-Delivery Market Nears $410 Billion
Biotechnology companies are increasingly focusing on platform technologies for drug delivery to maximize existing therapies, with the market projected to reach $410 billion, drawing investor interest to firms like Oncotelic Therapeutics.
Oncotelic Therapeutics Highlighted in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
Oncotelic Therapeutics is featured in a BioMedWire editorial that examines how biotech companies use advanced drug-delivery technologies and AI platforms to enhance therapies, highlighting Oncotelic's Sapu003, Deciparticle, and PDAOAI initiatives.
Lexaria Bioscience to Attend BIO International Convention Amid Record Business Development Interest
Lexaria Bioscience Corp. announces its attendance at the BIO International Convention in San Diego, highlighting a surge in partnership interest for its DehydraTECH drug delivery platform, which could lead to significant collaborations with pharmaceutical giants and biotech firms.
Oncotelic Therapeutics Advances Nanotech Drug Delivery Platform for Oncology and Rare Diseases
Oncotelic Therapeutics' inclusion in a BioMedWire editorial highlights the growing industry focus on advanced drug delivery technologies, with its Sapu003 program and Deciparticle platform exemplifying nanotechnology and AI-driven approaches to improve cancer therapy efficacy.
Oncotelic Therapeutics Advances Drug-Delivery Platform as Industry Focuses on Enhancing Existing Therapies
Oncotelic Therapeutics is progressing its Sapu003 program and Deciparticle platform to improve oncology drug delivery and bioavailability, aligning with industry trends favoring advanced delivery technologies over new compound development.
Oncotelic and Sapu Nano to Present Deciparticle Nanomedicine Platform at BIO 2026
Oncotelic Therapeutics and Sapu Nano will showcase their Deciparticle nanomedicine platform at the BIO International Convention 2026, highlighting ultra-small formulations for water-insoluble drugs and AI integration.
Oncotelic Therapeutics Advances CNS Drug Delivery Strategy Amid BBB Breakthroughs
Oncotelic Therapeutics' $12.5M monetization of its CNS delivery system highlights growing industry focus on blood-brain barrier bypass technologies, unlocking new biotech market opportunities.
Oncotelic Therapeutics Highlights CNS Drug Delivery Innovation in NetworkNewsAudio Editorial
Oncotelic Therapeutics was featured in a NetworkNewsAudio editorial discussing the challenges of the blood-brain barrier and the company's N2B delivery system, with implications for biodefense and Alzheimer's treatment.
Oncotelic Therapeutics Featured in Editorial Highlighting Intranasal Drug Delivery for Alzheimer's and Biodefense
Oncotelic Therapeutics' intranasal nose-to-brain delivery platform, featured in a BioMedWire editorial, addresses key challenges in CNS drug delivery for Alzheimer's disease and biodefense research by bypassing the blood-brain barrier.
Oncotelic’s Intranasal Brain Delivery Platform Highlighted as CNS Drug Development Gains Urgency
Oncotelic Therapeutics featured in BioMedWire editorial for its nose-to-brain delivery platform that bypasses the blood-brain barrier, with rising Alzheimer’s cases and biodefense needs driving demand for such technologies.
NHS Rolls Out One-Minute Immunotherapy Injection for Cancer Patients
The NHS in England is offering thousands of cancer patients a one-minute injection of pembrolizumab instead of a lengthy infusion, significantly reducing administration time.
Oncotelic Therapeutics Highlighted in BioMedWire Editorial on CNS Drug Delivery Innovation
Oncotelic Therapeutics was featured in a BioMedWire editorial examining breakthroughs in central nervous system drug delivery, highlighting its proprietary intranasal nose-to-brain delivery platform that aims to overcome the blood-brain barrier for neurological diseases and biodefense applications.
Oncotelic Therapeutics Targets CNS Drug Delivery as Brain Therapeutics Innovation Accelerates
Oncotelic Therapeutics is leveraging its intranasal nose-to-brain delivery platform to address the challenge of delivering therapeutics across the blood-brain barrier, targeting Alzheimer's disease and biodefense applications in a rapidly evolving biopharma landscape.
CNS Drug Delivery Innovations Address Critical Bottleneck in Biotech Market
Advancements in blood-brain barrier penetration technologies, such as Oncotelic's intranasal nose-to-brain system, are unlocking significant opportunities in the biotech sector by enabling targeted CNS therapies for diseases like Alzheimer's and bolstering biodefense preparedness.
Oncotelic Therapeutics Completes $12.5M Asset Transfer to Lunai Bioworks, Focusing on Nose-to-Brain Delivery for Alzheimer's and Biodefense
Oncotelic Therapeutics has transferred worldwide rights to its nose-to-brain delivery system for Alzheimer's and biodefense to Lunai Bioworks in exchange for $12.5 million in preferred stock, enabling it to monetize assets while retaining control for other indications like Parkinson's disease.
Oncotelic and Sapu Bioscience Define Sub-15 nm Nanoparticles as New Frontier in Drug Delivery
Oncotelic Therapeutics and Sapu Bioscience have published a landmark review establishing sub-15 nm nanoparticles as a breakthrough drug delivery platform capable of overcoming limitations of current therapies through enhanced tissue penetration and reduced toxicity.
Oncotelic Therapeutics Featured in Editorial on Nanomedicine Advances in Oncology
Oncotelic Therapeutics' inclusion in a NetworkNewsWire editorial highlights how its Deciparticle platform represents significant progress in nanomedicine for improving cancer drug delivery and reducing toxicity.
Oncotelic's Nanomedicine Platform Advances Cancer Treatment Through Enhanced Drug Delivery
Oncotelic Therapeutics' Deciparticle platform represents a significant advancement in nanomedicine that improves drug bioavailability and therapeutic effectiveness in oncology treatments.
Nanomedicine Breakthroughs Transform Cancer Drug Delivery and Bioavailability
Recent advancements in nanomedicine technology are revolutionizing oncology treatment by improving drug delivery systems, enhancing bioavailability, and potentially transforming underperforming cancer drugs into effective therapies through platforms like Oncotelic Therapeutics' Deciparticle.
Nanoparticle Breakthrough Offers New Hope for Alcohol-Related Liver Disease Treatment
Researchers have developed innovative nanoparticles that could combat scarring and inflammation in alcohol-related liver disease, potentially creating a treatment template applicable to other organs.
Sapu Nano Receives Australian Ethics Approval for Breast Cancer Drug Trial
Sapu Nano's Sapu003, an injectable form of Everolimus using proprietary nanoparticle technology, has received HREC approval for human clinical trials in Australia, potentially offering more effective breast cancer treatment through improved drug delivery.
Lexaria Bioscience Secures $4 Million in Capital to Advance 2026 Research and Development Initiatives
Lexaria Bioscience Corp. has completed a $4 million registered direct offering, providing crucial funding to advance its 2026 R&D and business development plans for its DehydraTECH drug delivery technology.
Lexaria Bioscience Secures $4 Million in Capital Through Registered Direct Offering
Lexaria Bioscience Corp. has raised $4 million through a registered direct offering, providing crucial working capital to advance its DehydraTECH drug delivery platform technology.
Lexaria's DehydraTECH Shows Enhanced Brain Delivery of Semaglutide in Preclinical Study
Lexaria Bioscience's drug delivery technology demonstrated improved brain distribution of GLP-1 drug semaglutide in rodents, potentially leading to better safety and efficacy for weight loss treatments.
Columbia University Scientists Develop Bacterial Trojan Horse Method to Deliver Anti-Cancer Viruses
Columbia University researchers have engineered bacteria to deliver cancer-killing viruses directly into tumors, bypassing immune system defenses and potentially revolutionizing cancer treatment approaches.
MIT Researchers Develop AI Method to Enhance RNA Nanoparticle Design for Improved Therapeutics
MIT researchers have created an AI-driven approach to optimize RNA nanoparticle design, potentially revolutionizing the delivery of RNA vaccines and treatments while highlighting the growing commercial impact of quantum computing companies like D-Wave.
BioMed X and Novo Nordisk Collaborate to Revolutionize Oral Peptide Drug Delivery
BioMed X and Novo Nordisk have partnered to tackle the challenge of oral peptide drug delivery, aiming to improve patient compliance and treatment efficacy through innovative formulation technologies.